Curis, Inc.
This article was originally published in The Gray Sheet
Executive Summary
Formation of the $600 mil.-cap biotechnology company focusing on regenerative medicine via the three-way merger of Creative Biomolecules, Ontogeny and Reprogenesis is complete July 31 following shareholder approvals. The deal was first announced in February (1"The Gray Sheet" June 12, p. 17). Nasdaq trading of Curis stock commenced on Aug. 1